Recent Updates
Recently added Catalysts
ACOG Positive Sentiment

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Thursday, October 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alpha Cognition Inc. has announced initial results from its CONVERGE study, which evaluates the use of ZUNVEYL (benzgalantamine) in long-term care settings. The study focuses on 180-day titration and medication patterns among residents. This real-world evidence aims to provide insights into the effectiveness and management of ZUNVEYL in a practical context.

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial results from the CONVERGE study show promising data.
  • Focus on real-world evidence may enhance understanding of ZUNVEYL's effectiveness.
  • Longitudinal data could support better medication management in long-term care.

Full Press Release Details

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan

Frequently Asked Questions

What is the CONVERGE study?

The CONVERGE study is an ongoing evaluation of ZUNVEYL's use in long-term care settings.

What medication is being studied in the CONVERGE program?

The study focuses on ZUNVEYL, which contains benzgalantamine.

What data is being analyzed in the CONVERGE study?

The study analyzes 180-day titration and medication patterns among residents.

Why is real-world evidence important?

Real-world evidence helps understand the effectiveness of medications in practical settings.

ShareAdd on Google
Tags: ACOG Alpha Cognition ZUNVEYL benzgalantamine long-term care CONVERGE
Last updated: Oct 1, 2026

Biotech snapshot

Cash runway
$41M liquidity · $2M/mo burn
~17 mo
Low dilution risk